Get ready to start hearing more about JADI CELL a

Quote:

---

Get ready to start hearing more about JADI CELL a cellular therapy pathway by TSOI to offer treatment for severly affected covid-19 patients
as TSOI CEO already disclosed TSOI will be filing an IND and soon.

---

Mesenchymal Stem Cells for use in Chronic Traumatic Encephalopathy (CTE), and Traumatic Brain Injury (TBI).
On December 10, 2018 Therapeutic Solutions International, Inc., announced the signing of an agreement between TSOI and Jadi Cell LLC for licensing of the Jadi Cell universal donor adult stem cell, as covered in US Patent No.: 9,803,176 B2 for use in Chronic Traumatic Encephalopathy (CTE), and Traumatic Brain Injury (TBI).

The Jadi Cell product, which belongs to the mesenchymal stem cell (MSC) family of cells, is a unique adult stem cell, which produces higher levels of therapeutic factors compared to other stem cells. The cells have demonstrated safety in animal models and pilot human trials.

StemVacs1 and StemVacs2 are not stem cell products - they are dendritic cells that have been activated to cause NK cells (natural killer cells) to eradicate pathogens from the human host.

Stem Cells, such as the Jadi Cell, (a mesenchymal like stem cell) are comprised of the dentate gyrus, subventricular zone, hepatic stem cells, cardiac stem cells, and hematopoietic stem cells. It is within these types of cell transplants we will use the conjugate as an adjuvant.